Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04831502
Other study ID # TAK-906-1005
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date April 2, 2021
Est. completion date February 2, 2022

Study information

Verified date March 2022
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to understand how TAK-906 tablets and capsules are processed by the body in healthy adults under fasting conditions and also how TAK-906 tablets are processed by the body when taken with a high fat high calorie breakfast compared to fasting. This study will require participants to stay at the clinical research unit for about 3 weeks to be monitored after receiving TAK-906.


Description:

The drug being tested in this study is called TAK-906. This study will compare the pharmacokinetics (PK) of single oral dose of 50 mg tablet (test [Treatment B]) relative to single oral dose of 50 mg capsule (reference [Treatment A]) under fasted conditions. The study will also explore the effect of food on 50 mg tablet formulation (Treatment C: high-fat/high-calorie meal) on TAK-906 PK following tablet administration relative to the fasted state (Treatment B). The study will enroll approximately 24 participants. Participants will be randomly assigned to 1 of the 2 treatment sequences. This single-center trial will be conducted in the United States. The overall time to participate in this study is approximately 60 days. Participants will be followed up for up to 14 days after the last dose of study drug for a follow-up assessment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2, 2022
Est. primary completion date February 2, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on participant self-reporting and urine cotinine test. 2. Body mass index (BMI) greater than or equal to (>=) 18.0 and less than (<) 30.0 kilogram per square meter (kg/m^2) at the screening. 3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs) performed at the screening visit and before administration of the initial dose of trial drug, as deemed by the investigator or designee. Exclusion Criteria: 1. Presence of infectious diseases (example, Coronavirus disease-19 [COVID-19] and flu) at the time of screening or check-in. 2. Any history of major surgery that may affect absorption, metabolism or excretion of study drug (example, intestinal resections, hepatectomy, nephrectomy, cholecystectomy), and/or digestive organ resection (except appendectomy). 3. History of any illness that, in the opinion of the investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study. 4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing. 5. Positive urine drug or alcohol results at screening or check-in. 6. Positive urine cotinine at screening. 7. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). 8. QT interval corrected for heart rate using Frederica's equation (QTcF) is greater than (>) 450 milliseconds (msec) or ECG findings are deemed abnormal with clinical significance by the Investigator or designee at screening. 9. Estimated creatinine clearance <90 milliliter per minute (mL/min) at screening. 10. Unable to refrain from or anticipates the use of: o Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. After first dosing, acetaminophen (up to 2 grams [g] per 24 hours) may be administered at the discretion of the investigator or designee; sponsor must be consulted prior to administering acetaminophen to a participants. 11. Has been on a diet incompatible with the on-study diet, in the opinion of the investigator or designee, within 30 days prior to the first dosing and throughout the study. 12. Is lactose intolerant or unable/unwilling to eat the high-fat, high-calorie breakfast. 13. Donation of blood or significant blood loss within 56 days prior to the first dosing. 14. Plasma donation within 7 days prior to the first dosing. 15. Participation in another clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dosing. The 30-day window or 5 half lives (whichever is longer) will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TAK-906
TAK-906 Tablets.
TAK-906
TAK-906 Capsules.

Locations

Country Name City State
United States Celerion Tempe Arizona

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric Mean Ratio of AUClast: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration Following TAK-906 Tablet Relative to TAK-906 Capsule Administration Under Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Primary Geometric Mean Ratio of AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity Following TAK-906 Tablet Relative to TAK-906 Capsule Administration Under Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Primary Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration Following TAK-906 Tablet Relative to TAK-906 Capsule Administration Under Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Number of Participants Reporting one or More Adverse Events (AEs) Baseline up to 14 days after the last dose of study drug in Period 5 (Day 31)
Secondary Number of Participants Reporting one or More Serious Adverse Events (SAEs) Baseline up to 14 days after the last dose of study drug in Period 5 (Day 31)
Secondary Geometric Mean Ratio of AUClast: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration Following TAK-906 Tablet in fed state Relative to TAK-906 Tablet in Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Geometric Mean Ratio of AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity Following TAK-906 Tablet in fed state Relative to TAK-906 Tablet in Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration Following TAK-906 Tablet in fed state Relative to TAK-906 Tablet in Fasted State Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Cmax: Maximum Observed Plasma Concentration After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary AUC%extrap: Percent of AUCinf Extrapolated After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Tmax: Time to Reach Maximum Plasma Concentration After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Tlag: Lag Time to First Quantifiable Concentration After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Kel: Apparent Terminal First Order Elimination Rate Constant After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary CL/F: Apparent Plasma Clearance After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Secondary t½: Terminal Half-life After Single Dose of TAK-906 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1